Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found an association between a splice site variant in the KRT71 gene and curly hair in Selkirk Rex cats, identifying a significant locus on chromosome B4.

This study found that modeling and simulation effectively informed decision-making and dose selection for ritlecitinib in treating alopecia areata, supporting an accelerated drug development strategy.

The study found that cyproterone acetate could be released over 15 days using coconut oil mixed with certain wax inhibitors, though further safety studies are needed.

In this study, Rosa rugosa water extract improved hair length and thickness in a mouse model of DHT-induced alopecia by enhancing the expression of hair growth-promoting factors while inhibiting growth-suppressive proteins, suggesting its potential as a natural therapy for hair loss prevention.

In this study, the safety profiles of four treatments for early rheumatoid arthritis were assessed over one year, and the most serious side effects necessitating treatment discontinuation were noted in the leflunomide group, whereas no such withdrawals occurred in the methotrexate plus prednisolone group.

This study reports a novel mutation in the TP63 gene associated with T and B cell lymphopenia in an EEC patient, suggesting that EEC diagnosis should include TREC assay and evaluation for immunodeficiency.

This source reviews the common skin-related side effects of tyrosine kinase inhibitors in treating endocrine cancers and emphasizes that proactive, multidisciplinary management can effectively control these adverse events without compromising cancer treatment efficacy.

This review discusses the development and potential therapeutic effects of nitroxide small molecule agents for age-related macular degeneration and cardiovascular disease, but reports no new clinical results.

This study found that ritlecitinib, approved for alopecia areata in patients aged 12 and older, has an acceptable safety profile with mild to moderate side effects and no increase in serious adverse events compared to placebo.

In this study, researchers developed a new prostate cancer imaging agent, a [99m Tc]tricarbonyl complex derived from finasteride, which demonstrated high radiochemical purity and significant uptake in the prostate of a rat model, suggesting its potential for noninvasive prostate cancer imaging.

This article reviews new drug combinations and unique agents for rheumatoid arthritis but reports no clinical results; the authors highlight several promising compounds awaiting approval.

This study found that RCS-01 cell therapy for aged skin was well tolerated and associated with increased gene expression related to extracellular matrix homeostasis, suggesting potential skin improvement.

This study found that thyrotropin-releasing hormone (TRH) acts as a potent stimulator of hair growth in human scalp hair follicles, promoting elongation and prolonging the anagen phase.

This narrative review found that ritlecitinib shows consistent effectiveness and a favorable safety profile for treating alopecia areata in clinical trials and real-world settings, with progressive hair regrowth observed, particularly when treatment is initiated early and maintained appropriately.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

This study found that paclitaxel poliglumex showed limited effectiveness and was relatively well tolerated in post-menopausal women with advanced NSCLC, suggesting further testing of this treatment may not be justified.

This study identified a novel KRT86 mutation associated with autosomal dominant monilethrix, expanding understanding of its genetic basis beyond known motifs.

This study found that TRH modulates specific keratins in human scalp tissue, suggesting its potential influence on hair growth and the need for further exploration of neuroendocrine controls in keratin expression.

This review discusses the diverse pharmacological activities of T. procumbens, such as hypotensive and hair growth-promoting effects, but reports no new clinical findings.

This review explores molecular targets for head and neck squamous cell carcinoma and discusses potential advancements in radiopharmaceuticals for targeted radionuclide therapy, reporting no new clinical results.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

This review discusses the development and clinical progression of PROTAC technology for targeted protein degradation, highlighting its potential to address previously "undruggable" targets but reports no new clinical results.

Reduced TRPS1 leads to increased STAT3 and SOX9 in hair follicles, affecting hair growth.

This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.